… tumor DNA (ctDNA) and checkpoint inhibitor response. … with response to checkpoint
inhibitors in several malignancies (8… reactivated by checkpoint inhibitors, recognizes tumor cells …

… checkpoint inhibitors (ICIs). … tumor DNA (ctDNA) change in response to treatment is unclear,
especially in unselected advanced solid tumors treated with immune checkpoint inhibitors (…

A more common and noninvasive predicting biomarker for programmed cell death 1 (PD-1)
antibody remains to be explored. We assessed 46 patients with advanced gastric cancer …

… Background: The use of circulating tumor DNA (ctDNA) to reflect clinical benefits of
advanced non-small cell lung cancer (NSCLC) patients during immune checkpoint inhibitor (ICI) …

… checkpoint inhibitors (ICIs) in patients with non–small-cell lung cancer (NSCLC) is of high
clinical relevance. Given that circulating tumor DNA (ctDNA) reflects the total body tumor …

PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline
settings, identifying early indicators of response is needed. Recent studies suggest a role for …

… tumor DNA (ctDNA) level is a proxy of early tumor response to immunotherapy according to
response evaluation criteria in solid tumors … 100) receiving immune checkpoint inhibitors (ICI) …

… treatments on tumors. In addition, ctDNA might be preferable to monitor tumor development
… in ctDNA could predict response to immune checkpoint inhibitor (ICI). Several studies have …

… checkpoint inhibition, but predictive biomarkers are unknown. We analyzed tumor DNA …
cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy in patients with sarcoma. …

… Change in on-treatment circulating tumor DNA (ctDNA) quantity and the durability of response
to immune checkpoint inhibitors (ICIs) in the discovery cohort. (A) Swimmer plot illustrating …